CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease - Summary - MDSpire
Feature

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

  • April 13, 2026

  • 2 min

Share

An experimental gene-editing therapy utilizing CRISPR-Cas12a, named renizgamglogene autogedtemcel, shows early promise in treating severe sickle cell disease. In a phase 1-2 study involving 28 patients, total hemoglobin levels rose significantly from 9.8 g/dL to 13.8 g/dL within six months, and fetal hemoglobin increased dramatically from 2.5% to 48.1%. Remarkably, 27 patients experienced no severe vaso-occlusive events. Lead author Rabi Hanna emphasized the potential of this approach as a functional cure, differing from traditional treatments. Although the trial was cut short, the findings highlight the efficacy of promoter editing in reactivating fetal hemoglobin.

Original Source(s)

Related Content